LSFG-SKIN, Laser Speckle Flowgraphy

Randy Kardon

Status: Terminated

Conditions: Autonomic Neuropathy; Radiation Injuries; Chemotherapy Effect; Stroke; Vascular Ischemia; Heart Failure; Headache; TIA; Hypertension; Uveitis; Multiple Sclerosis; Intracranial Hemorrhages; Migraine; Burns; Pain; Scleritis

Treatments: Device: laser speckle flowgraphy

Study type: Interventional

Funder types: Other

Identifiers

NCT03660618

201702725

Details and patient eligibility

About

The purpose of this project is to quantify normal and abnormal skin blood flow regionally in different areas of the body(face, extremities, over burns and wounds) at baseline and over time in response to treatment or environmental changes, such as temperature, light and pressure.

Full description

Laser speckle skin blood flow (LSFG-SKIN) will be recorded in normal subjects and in patients with disorders affecting skin capillary perfusion, which may include cardiovascular disorders, dermatologic disorders, skin wounds, ocular disorders, psychiatric disorders, and neurologic disorders.

Enrollment: 1 patient

Sex: All

Ages: 18 to 90 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Controls

●Healthy normal control subjects ages 18-90

Cardiology Subjects

• Ages 18-90
• History of dysrhythmia, heart failure, cardiac ischemia, hypertension, peripheral vascular disease

Dermatology Subjects

• Ages 18-90
• History of inflammatory and cancerous lesions

Endocrine Subjects

• Ages 18-90
• History of diabetes, thyroid disease

Neurology Subjects

• Ages 18-90
• History of dementia, headaches, Parkinson's, light sensitivity, stroke, TIA, multiple sclerosis

Psychiatry Subjects

• Ages 18-90
• History of bipolar, schizophrenia, anxiety, depression

Surgery Subjects

• Ages 18-90
• History of skin wounds(trauma, chemotherapy, radiation), thermal burns, or plastic and reconstructive surgical procedures.

Ophthalmology Subjects

• Ages 18-90
• History of ocular disorders caused by hypo perfusion or inflammatory disorders

Exclusion criteria

Controls

• Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts are okay.
• Angle closure glaucoma

Cardiology Subjects

• Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts are okay.

• Angle closure glaucoma

  3. Dermatology Subjects

• Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts are okay.

• Angle closure glaucoma

Endocrine Subjects

• Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts are okay.
• Angle closure glaucoma

Neurology Subjects

• Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts are okay.
• Angle closure glaucoma

Psychiatry Subjects

• Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts are okay.
• Angle closure glaucoma

Surgery Subjects

• Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts are okay.
• Angle closure glaucoma

Ophthalmology Subjects

• Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts are okay.
• Angle closure glaucoma

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

1 participants in 1 patient group

Clinic Subjects

Other group

Description:

cardiology subjects, dermatology subjects, endocrine subjects, neurology subjects, psychiatry subjects, surgery subjects, ophthalmology subjects.

Treatment:

Device: laser speckle flowgraphy